GFAP and myeloid sarcoma: BDNF, NfL and GFAP concentrations in serum and CSF were assessed in 106 treatment na﻿ïve patients with MS (pwMS) as well as 73 patients with other inflammatory/non-inflammatory neurological or somatoform disorders using a single molecule array HD-1 analyser.